Company Description
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.
The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair.
Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease.
The company also sells Longevity products that focuses on personal healthcare, including longevity dietary supplements.
Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023.
The company was founded in 2009 and is headquartered in Holliston, Massachusetts.
| Country | MA |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
Contact Details
Address: 84 October Hill Road, Suite 11 Holliston, Massachusetts 01746 United States | |
| Phone | (774) 233-7300 |
Stock Details
| Ticker Symbol | HRGN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001563665 |
| Employer ID | 45-5210462 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Junli He | Chief Executive Officer and Chairman |
| Yu Hong | President |
| Dr. William L. Fodor Ph.D. | Chief Scientific Officer |
| Joseph L. Damasio Jr. | Chief Financial Officer |
| Dr. Shunfu Hu Ph.D. | Vice President of Business Development and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 8-K | Current Report |
| Nov 16, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |